Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

US7358353B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Aya Jakobovits · Beverly Hills, US
• Robert Kendall Morrison · Santa Monica, US
• Arthur B. Raitano · Los Angeles, US
• Pia M. Challita-Eid · Calabasas, US
• Juan J. Perez-Villar · Mercerville, US
• Karen Jane Meyrick Morrison · Santa Monica, US
• Mary Faris · Los Angeles, US
• Wangmao Ge · Tampa, US
• Jean Gudas · Los Angeles, US
• Steven B. Kanner · Berkeley, US

Key dates

• Filing date: Feb 10, 2004
• Grant date: Apr 15, 2008
• Expiry date: Jul 11, 2024

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T436/25
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.